Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Background: New tumour biomarkers are being intensely investigated for malignant mesothelioma (MM).Fibulin-3 is produced in MM but its role remains uncertain. The aim of this study was to evaluate the validityof measuring serum fibulin-3 in the diagnosis and prognosis of MM. Materials and
Methods: This prospectivestudy was performed on 43 patients and 40 healthy controls who were admitted to our hospital between January2012 and January 2014. Data from MM patients, including demographic and clinical features, routine laboratorydata, levels of serum fibulin-3, and treatment outcomes were defined as potential prognostic factors. The receiveroperating characteristic (ROC) curve for fibulin-3 was used to detect the cut-off value with highest sensitivityand specificity. Univariate survival analysis was performed using the Kaplan-Meier method in patients with MM.Afterwards, the possible factors identified with univariate analyses were entered into the cox regression analysis.
Results: Our results revealed that patients with MM had significantly higher serum levels of fibulin-3 thancontrols. The results showed that the best cut-off point was 36.6 ng/ml with an AUC (area under the curve)=0.976,sensitivity=93.0% and specificity=90.0. In our study, the initial significant poor prognostic factors were advancedstage, high white blood cell count, high platelet count, high C-reactive protein (p<0.05 for each variable). Later,according to multivariate analysis the results showed only advanced stage as significant parameter (p=0.040).
Conclusions: We determined that real use for serum fibulin-3 was not for prognosis but for diagnosis in MM.Also advanced stage was associated with poor MM prognosis.